New medications approved for the treatment of systolic heart failure may be underutilized
This week's FierceBiotech is brought to you by Veradigm. Trouble viewing? Click here.
|
| New medications approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Heart failure is a complex clinical syndrome arising from structural or functional impairments of ventricular filling or ejection of blood. With its increasing prevalence and the aging of the population, the economic burden of heart failure on the US healthcare system is substantial and continues to increase. High morbidity and mortality make heart failure a significant concern for patients and their families. Management is challenging, especially in the presence of comorbidities, which can be risk factors for developing heart failure as well as complicating factors in established heart failure. The gaps in use and dosing of evidence-based, guideline-recommended therapies suggest a care deficit exists such that treatment remains suboptimal for a significant number of heart failure patients. Read more to learn how real-world evidence derived from de-identified patient information available in electronic health record (EHR) platforms may be leveraged to inform and advance appropriate care plans in heart failure. |
|
|
Want to reach 137,000+ FierceBiotech subscribers with your own message? Contact [email protected] or call 202-824-5074.
About this email: In order to receive FierceBiotech for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceBiotech. Click here to unsubscribe. Refer to our Privacy Policy. FierceMarkets, a division of Questex, LLC 1900 L St. NW Suite 400 Washington, DC 20036 |